BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-2.70 · Revenue $1.01B · 12 analysts
Est. EPS $0.06 · Revenue $428.84M · 2 analysts
Est. EPS $0.43 · Revenue $510.65M · 2 analysts
Est. EPS $0.13 · Revenue $1.68B · 12 analysts
EPS $-0.88 · Revenue $116.63M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $502.1M | +126.3% | +14.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-729.3M | -36.1% | +7.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +94.4% | -4.0% | -1.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -113.3% | +57.6% | +11.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -145.3% | +39.8% | +18.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-447.0M | +14.3% | -13.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -89.0% | +62.1% | +0.8% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -131.4% | -11.5% | +33.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.62x | -43.9% | -15.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $936.0M | +1.8% | -11.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.79 vs -3.44 | -10.1% | -0.78 vs 0.06 | -1375.3% |
| Revenue Surprise | $502.1M vs $496.3M | +1.2% | $222.4M vs $428.8M | -48.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Kumar Neil | director, officer: Chief Executive Officer | Common Stock | D | 8,100 | $83.86 |
| Aug 19, 2026 | Kumar Neil | director, officer: Chief Executive Officer | Common Stock | D | 1,800 | $84.69 |
| Aug 19, 2026 | Kumar Neil | director, officer: Chief Executive Officer | Common Stock | D | 100 | $85.65 |
| Aug 18, 2026 | Kumar Neil | director, officer: Chief Executive Officer | Common Stock | D | 1,900 | $81.15 |
| Aug 18, 2026 | Kumar Neil | director, officer: Chief Executive Officer | Common Stock | D | 17,279 | $82.21 |
Operator: Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. Before we begin, I would like to remind everyone that today's call may contain forward looking statements within the meaning of the federal securities laws. Including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward looking statements. For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today and the company undertakes no obligation to update any forward looking statements made during this call except as required by law. With that completed, BridgeBio, you may begin your conference. Chinmay Shukla: Good afternoon, everyone, and thank you for joining BridgeBio Pharma's second quarter 2026 earnings call. I'm Chinmay Shukla, senior vice president, strategic finance. With me today are Neil Kumar, our CEO who'll walk through our commercial pipeline and business updates, Matt Outten, our chief commercial officer, who'll provide additional detail on our Attruby and our launch readiness, and Tom Trimarchi, our president and CFO, who will review our financial results. During today's call, we will cover another quarter of consistent growth for Attruby, along with new data reinforcing its clinical differentiation. Including the first evidence of direct kidney protection in ATTR-CM. We will then turn to the pipeline where this quarter all three of our late stage programs moved from data into being with the FDA. With our first PDUFA date now set for November 27, 2026. And we will review our financial position including the $1 billion preferred equity financing completed on July 1, 2026, and how it supports the three launches ahead of us. Following our prepared remarks, we will open the call for questions. For the Q&A session, we will be joined by Ananth Sridhar, Christine Siu and Justin To, who lead our programs with encaleret, BBP-418, and infigratinib, respectively. With that, I'll turn it over to Neil. Neil Kumar: Thanks, Chinmay, and thanks, everyone, for joining today. As always, these calls are where we communicate relevant aspects of our business to investors and so we welcome your questions and feedback. In sessions past, we've had occasion to marry comments on the portfolio with comments regarding financing and strategy. Today, however, I wanna focus entirely on the portfolio itself and the progress being made across research, development, and commercial. I'm going to …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Neil Kumar | Co-Founder, Chief Executive Officer & Director | USD 2,463,318 | — | 1979 | Active |
Uma Sinha | Chief Scientific Officer | USD 1,313,457 | — | 1958 | Active |
Thomas Trimarchi | Chief Financial Officer & President | USD 1,229,882 | — | 1985 | Active |
Charles J. Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director | USD 574,167 | — | 1948 | Active |
Frank McCormick | Co-Founder, Chairman of Oncology & Director | USD 550,000 | — | 1950 | Active |
Richard H. Scheller | Chairman of Research & Development | USD 509,622 | — | 1953 | Active |
Matthew Outten | Chief Commercial Officer | — | Male | 1974 | Active |
Maricel Apuli | Chief Accounting Officer | — | Female | 1977 | Active |
Eric Michael David | Chief Executive Officer of Gene Therapy | — | — | 1972 | Active |
Eli Wallace | Chief Scientific Officer of Oncology | — | Male | 1967 | Active |
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
